Huntington's disease drug: Teva Pharma settles patent dispute with Lupin, continues to litigate against Aurobindo

Under the terms of the settlement agreement, the litigation between the parties in the United States District Court for the District of New Jersey will be ended, and Lupin will have a license to sell its generic product beginning April 2033, or earlier under certain circumstances.

Read also: Bristol Myers sues AstraZeneca over cancer-treatment patents

AUSTEDO is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

TD is a movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals. Safety and effectiveness in pediatric patients have not been established.

Read also: Ahead of Linagliptin going off-patent, NPPA fixes retail price of its FDC with Metformin

"Teva believes that the settlement with Lupin is a further reflection of the strength of its intellectual property covering its AUSTEDO product," the release stated.

On March 9, 2022, the U.S. Patent Office Patent Trial and Appeal Board declined to institute an Inter Partes Review of Teva's compound patent for deutetrabenazine in response to a petition submitted by Apotex. Teva will continue to litigate the ongoing patent infringement suit it brought against Aurobindo regarding Aurobindo's ANDA for a generic deutetrabenazine product.

Read also: Violation of Drugs Patents: Boehringer Ingelheim demands authorities set mechanisms in place